---
trial_id: 486
discovery_date: 2022-04-05 21:16:14.466625
date: 2022-04-05 21:16:14.466625
title: "A randomized, double-blind, double-dummy, parallel-group study, comparing the efficacy and safety of remibrutinib versus teriflunomide in participants with relapsing multiple sclerosis, followed by..."
summary: |
  <p>EudraCT Number: 2020-005929-89<br />Sponsor Protocol Number: CLOU064C12302<br />Sponsor Name: Novartis Pharma AG<br />Start Date: 2022-02-01<br />Medical condition: Multiple Sclerosis<br />Disease: <br />Version: 21.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10080700<br />Term: Relapsing multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-005929-89/SE">SE</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-005929-89/ES">ES</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-005929-89/SI">SI</a> (Ongoing)</p>
link: 'https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-005929-89'
published_date: NaT
trial_source: Clinical Trials Register Europe
relevant: 
options:
  unlisted: false
---
<p>EudraCT Number: 2020-005929-89<br />Sponsor Protocol Number: CLOU064C12302<br />Sponsor Name: Novartis Pharma AG<br />Start Date: 2022-02-01<br />Medical condition: Multiple Sclerosis<br />Disease: <br />Version: 21.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10080700<br />Term: Relapsing multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-005929-89/SE">SE</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-005929-89/ES">ES</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-005929-89/SI">SI</a> (Ongoing)</p>